Posterior Segment Company Showcase - Ohr pharmaceutical

Posterior Segment Company Showcase - Ohr pharmaceutical

• 1.
  Ophthalmology Innovation Summit AAO2016 October 13, 2016
• 2.
  Forward Looking Statement Thispresentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward looking statements are made only as the date thereof, and Ohr undertakes no obligation to update or revise the forward looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.
• 3.
  Ohr Pharmaceutical Overview •Ophthalmology-focused company with compelling early and late stage pipeline – Utilize innovative drug development strategies to meet patient needs in ocular disease • Lead program – Squalamine lactate ophthalmic solution – Phase 3 program in wet AMD actively enrolling – Marked visual acuity benefit of combination therapy using topical Squalamine and anti-VEGF injections in phase 2 study in wet AMD • Additional indications for Squalamine – Retinal vascular occlusive disease and diabetic retinopathy – Visual acuity benefit seen in investigator sponsored trial in retinal vein occlusion • Sustained release platform technology – Four active internal programs • Strong management team with deep expertise in ophthalmology drug development
• 4.
  Unmet Need: ATopical Therapy That Improves and Maintains VA Gains Increase Initial Visual Acuity Gains Maintain Long Term Visual Acuity Gains MeanChangeinETDRSVisualAcuity(Letters)
• 5.
  Squalamine in theWet AMD Armamentarium VEGF-R1 Lucentis® Genentech/Novartis Avastin® Genentech/Roche RTH258 Alcon/Novartis VEGF VEGF-R2 Eylea® Regeneron/Bayer PDGF Fovista® Ophthotech/Novartis REG-2176 Regeneron Squalamine PDGF-R bFGF-R Extracellular Intracellular DARPin Allergan Prevents downstream signaling of multiple angiogenic factors
• 6.
  Vascular Biology ofCNV 12% 39% 49% Incidence Mixed Classic/Occult CNV Occult CNV Classic CNV AJO 2014; 158: 769-779
• 7.
  Responsive to anti-VEGFtherapy • Reduction in leakage and at least partial vascular involution • Located between the retina and retinal pigment epithelium (RPE) • Vessels tend to be very rapidly growing and frequently manifest symptoms early with leakage and bleeding which causes vision loss • Mostly immature vessels with little pericyte coverage in the initial stages of development Classic Neovascularization
• 8.
  Primary target forcombination therapy • More resistant to anti-VEGF therapy – reduction in leakage but little effect on anatomy • Located beneath the RPE, just above the normal choroidal vascular layers • Vessels grow slowly and (as much as 30%) may be asymptomatic and only later develop exudation and become clinically evident • More mature vasculature and more pericyte coverage Occult Neovascularization
• 9.
  Phase 2 Studyin Wet AMD Mandated Lucentis retreatment SD-OCT evidence of: • Any Retinal Cystic Changes • Any Retinal Fluid • Any Subretinal Fluid • Meaningful RPE Elevation Treatment-naïve patients with exudative AMD • All lesion compositions (classic, mixed and occult only) • Up to 12 disc areas in size • VA 20/40 to 20/320 Lucentis® is a registered trademark of Genentech Inc.
• 10.
  Positive Visual Outcomesin Squalamine Combination Therapy Driven by Occult CNV Size • Occult CNV size at baseline directly correlates with week 36 visual acuity outcomes in Squalamine combination therapy • This was independent of the presence/absence of classic CNV • This relationship was not observed with ranibizumab monotherapy treatment. • Consistent positive visual acuity benefit with Squalamine combination therapy in occult CNV < 10mm2 (~ 4 Disc Areas) Occult CNV < 10mm2 Occult CNV > 10mm2
• 11.
  Positive Visual Outcomesin Occult CNV < 10mm2 Efficacy Consistent Through Month 9 Mean Change in Visual Acuity (Letters) +5.3 letters P = .038 MeanChangeinETDRSVisualAcuity(Letters) Exploratory p-value
• 12.
  Positive Visual Outcomesin Occult CNV < 10mm2 Efficacy Consistent Through Month 9 Proportion with > 3 line VA Gain 54% Benefit ProportionofSubjectswith≥3LineGains
• 13.
  Improved Functional VisionOutcome Better Final VA with Squalamine Combination Therapy *One additional subject did not have a VA assessment at week 36 MeanETDRSVisualAcuity(Letters)
• 14.
  Phase 3 StudyDesign Treatment-naïve patients with exudative AMD • All lesion compositions (classic, mixed and occult only) • Occult CNV (if present) <10 mm2 • VA 20/40 to 20/320 Primary Endpoint: Visual acuity gain at month 9
• 15.
  Squalamine Lactate OphthalmicSolution Summary • Squalamine has the potential to be a convenient and cost- effective therapy in retinal disease • Indication in Exudative AMD – Unmet need for improved vision beyond anti-VEGF monotherapy – Strong phase 2 data supporting role of squalamine combination therapy in providing clinically meaningful vision gains • Use with Multiple Anti-VEGF Agents – Combination effect with all current and future anti-VEGF agents – Topical delivery adaptable for use with any anti-VEGF treatment regimen/frequency • Multiple back-of-the-eye indications – Initial data in investigator led clinical trial evaluating retinal vein occlusion indicate improved vision outcomes – Suggests potential role in retinal vascular disease (RVO and DME)
• 16.
  Ohr Pharmaceutical Overview •Ophthalmology-focused company with compelling early and late stage pipeline – Utilize innovative drug development strategies to meet patient needs in ocular disease • Lead program – Squalamine lactate ophthalmic solution – Phase 3 program in wet AMD actively enrolling – Marked visual acuity benefit of combination therapy using topical Squalamine and anti-VEGF injections in phase 2 study in wet AMD • Additional indications for Squalamine – Retinal vascular occlusive disease and diabetic retinopathy – Visual acuity benefit seen in investigator sponsored trial in retinal vein occlusion • Sustained release platform technology – Four active internal programs • Strong management team with deep expertise in ophthalmology drug development
• 17.
  2